The EU-CARDIOPROTECTION COST Action (CA16225) is a pan-European research network of leading experts in experimental and clinical cardioprotection, whose overall aim is to improve the translation of novel experimental cardioprotective therapies into the clinical setting for patient benefit.
Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action – CA16225May 23, 2018 | General
Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are the leading causes of death and disability in Europe and worldwide. As such, new treatment strategies are needed to protect the heart against acute ischemia/reperfusion injury (IRI) in order to preserve cardiac function and prevent adverse left ventricular remodeling and HF – […]
Special Issue “Novel Molecular Targets for Cardioprotection: The EU-CARDIOPROTECTION COST Action (CA16225)”May 22, 2018 | General
We have a special issue in Int J Mol Sci – [IF 3.226] – see link – http://www.mdpi.com/journal/ijms/special_issues/targets_for_cardio We invite you to submit original and review articles on the theme of cardioprotection with a special focus on novel molecular targets (deadline for submission Nov 2018). If you are interested to submit an article to this […]
COST Action CA15203 MitoEAGLEMay 14, 2018 | General
COST Action CA15203 MitoEAGLE Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping The objective of the MitoEAGLE network is to improve our knowledge on mitochondrial function in health and disease related to Evolution, Age, Gender, Lifestyle and Environment. Every study of mitochondrial (mt) function and disease is faced with EAGLE as the essential background conditions characterizing the individual patient, […]